KMDA
Kamada Ltd
A maker of plasma-derived and recombinant protein therapies, Kamada Ltd produces medicines for people with rare conditions. Its flagship product, GLASSIA, treats alpha-1 antitrypsin deficiency, a genetic disorder that can damage the lungs and liver, and the company also makes KamRAB for rabies exposure and KamRho for Rh incompatibility in pregnancy. Founded in Israel in 1990, the company takes its name from the Hebrew word for "longing," and its therapies reach patients in dozens of countries.
CINS: M6240T109ISIN: IL0010941198HealthcareIL2 holders
Total Value
$4.07M
Total Shares
526.6K
Net Share Change
-12.5K
Activity
2 selling
Investor
Value
Shares
Weight
Change
